✦ LIBER ✦

Mitoxantrone and Cytarabine Induction, High-Dose Cytarabine, and Etoposide Intensification for Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia: Children's Cancer Group Study 2951

✍ Scribed by Wells, R. J.

Book ID: 126311720
Publisher: American Society of Clinical Oncology
Year: 2003
Tongue: English
Weight: 302 KB
Volume: 21
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2003.06.128

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mitoxantrone, etoposide, and cytarabine

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia : An Eastern Cooperative Oncology Group pilot study

✍ Martin S. Tallman; Sandra Lee; Branimir I. Sikic; Elisabeth Paietta; Peter H. Wi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Background: One potential mechanism of drug resistance to chemotherapy is the overexpression of multidrug resistance (mdr) genes coding for p-glycoprotein (p-gp), which leads to reduced intracellular retention of chemotherapy. this study tested the efficacy and toxicity of mitoxantrone, etoposid

Mitoxantrone and etoposide with or witho

Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia

✍ Steven M. Trifilio; Alfred W. Rademaker; Diane Newman; Katherine Coyle; Katrin C 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 180 KB

Pharmacology of cytarabine given as a co

Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia

✍ Fevzi Ozkaynak, M.; Avramis, Vassilios I.; Carcich, Sherri; Ortega, Jorge A. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 3 views

Background. The outcome of patients with acute myeloid leukemia (AML) who relapse or fail to achieve an initial remission has been dismal. Procedure. Fifteen pediatric patients with AML, 4 relapsed and 11 primary refractory, were reinduced with a loading bolus of 0.5 g/m 2 cytarabine (ara-C) followe

A Phase 2 study of bortezomib combined w

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group

✍ Horton, Terzah M.; Perentesis, John P.; Gamis, Alan S.; Alonzo, Todd A.; Gerbing 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB